FDA
The latest in health news: The FDA is finally reviewing homeopathic products to decide whether they should go under same approval process as conventional drugs, a new study shows why napping in carseats and strollers could be dangerous for your infant, and Columbia faculty speak out for or against Dr. Oz; we aren't sure.
An article in yesterday s NYTimes revealed that two U.S.Senators Dianne Feinstein (D-CA) and Susan Collins (R-ME) are proposing a bill to tighten the FDA s regulatory oversight of the cosmetics
Conflict of interest at the FDA, Part Deux: The tobacco advisory panel, well-stocked with ideologically devoted anti-harm reduction membership, could not determine that snus is less harmful than smoking. Shame!
The answer is you won t believe it. ACSH s Dr. Josh Bloom s new Science 2.0 piece examines why GNC and other supplement retailers are allowed to sell a stimulant called BMPEA
The Safe and Accurate Food Labeling Act, first proposed by Representative Mike Pompeo (R-Kan) and Representative G.K. Butterfield (D-N.C.) is once
Recently, the US Food and Drug Administration (FDA) issued a warning to consumers and pharmacies not to rely on over-the-counter asthma products labeled as homeopathic. In their alert, they write:
Although anti-GMO activists will undoubtedly disagree, we here at ACSH compliment the FDA for its approval of genetically engineered (GMO) apples and potatoes.
Dr. Gilbert Ross in Science 2.0, March 20, 2015
Our nation s most influential, respected and powerful public health officials and academics are engaged in a vast,corrupt and fraudulent conspiracy to keep
The American Council on Science and Health, a public health education and consumer advocacy nonprofit devoted throughout our 35 year history to the promotion of sound science in public health policy, urges the FDA to promote
Last month, the New York State Attorney General (AG) had herbal supplements sold at GNC, Walgreens, Target, and Walmart tested, and found the supplements did not contain the herbs on the label 80 percent of
A big story today is that the FDA, for the first time, has approved a so-called biosimilar drug.
The thrust of the news is mostly regulatory and economic: